The 10 linked references in paper A. Ignatova V., A. Stroganova M., S. Dranko L., A. Senderovich I., S. Podvyaznikov O., А. Игнатова В., А. Строганова М., С. Дранко Л., А. Сендерович И., С. Подвязников О. (2017) “Особенности мутаций в генах KIT, NRAS и BRAF при меланоме слизистых оболочек верхних дыхательно-пищеварительных путей (исследование с участием 21 пациента) // KIT, NRAS and BRAF mutations in head and neck (upper aerodigestive tract) mucosal melanoma (a study of 21 cases)” / spz:neicon:ogsh:y:2017:i:1:p:69-74

  1. Lourenço S.V., Sangueza M., Sotto M.N. et al. Primary oral mucosal melanoma: a series of 35 new cases from South America. Am J Dermatopathol 2009;31:323–30. DOI: 10.1097/DAD.0b013e3181a0d37c. PMID: 19461235.
  2. Owens J.M., Roberts D.B., Myers J.N. The role of postoperative adjuvantradiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg 2003;129:864–8. DOI: 10.1001/archotol.129.8.864. PMID: 12925346.
  3. Papaspyrou G., Garbe C., Schadendorf D. et al. Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors. Melanoma Res 2011;21: 475–82. DOI: 10.1097/CMR.0b013e32834b58cf. PMID: 21897303.
  4. Davies H., Bignell G.R., Cox C. et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949–54. DOI: 10.1038/nature00766. PMID: 12068308.
  5. Omholt K., Grafström E., KanterLewensohn L. et al. KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res 2011;17:3933–42. DOI: 10.1158/1078-0432.CCR-10-2917. PMID: 21680547.
  6. Turri-Zanoni M., Medicina D., Lombardi D. et al. Sinonasal mucosal melanoma: molecular profile and therapeutic implications from a series of 32 cases. Head Neck 2013;35:1066–77. DOI: 10.1002/hed.23079. PMID: 22791410.
  7. Ascierto P.A., Minor D., Ribas A. et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013;31(26):3205–11. DOI: 10.1200/JCO.2013.49.8691. PMID: 23918947.
  8. Chapman P.B., Hauschild A., Robert C. et al. (BRIM-3 Study Group.). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507–16. DOI: 10.1056/NEJMoa1103782. PMID: 21639808.
  9. Zebary A., Jangard M., Omholt K. et al. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases: British Journal of Cancer 2013;109:559–64. DOI: 10.1038/bjc.2013.373. PMID: 23860532.
  10. 4;20(12):3328–37. DOI: 10.1158/1078-0432.CCR-14-0093. PMID: 24714776. 20. Beadling C., Jacobson-Dunlop E., Hodi F.S. et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14:6821–8. DOI: 10.1158/1078-0432.CCR-08-0575. PMID: 18980976.